Back to Search
Start Over
Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus.
- Source :
-
International journal of molecular sciences [Int J Mol Sci] 2020 May 14; Vol. 21 (10). Date of Electronic Publication: 2020 May 14. - Publication Year :
- 2020
-
Abstract
- We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xMAP technology, and nuclear antigen autoantibody specificities using addressable laser bead immunoassay. In patients with detectable levels at baseline, interferon (IFN)-α2 levels were lower at month 6 (median; interquartile range (IQR): 8.9; 1.5-54.9 pg/mL) versus baseline (28.4; 20.9-100.3 pg/mL; p = 0.043). Interleukin (IL)-6 (baseline: 7.1; 2.9-16.1 pg/mL) decreased from month 6 (0.5; 0.5-6.3 pg/mL; p = 0.018) and throughout a 24 month follow-up. IL-10 (baseline: 12.6; 2.8-29.7 pg/mL) showed more rapid decreases from month 3 (1.8; 0.6-9.1 pg/mL; p = 0.003). Levels of anti-dsDNA ( p < 0.001), anti-Smith antigen (Sm) ( p = 0.002), anti-U1 small nuclear ribonucleoprotein (U1RNP) ( p < 0.001), anti-Sm-U1RNP complex ( p = 0.028), and anti-ribosomal P ( p = 0.012) antibodies decreased from month 3 and remained decreased. Anti-Sm positivity at baseline was associated with higher probability and/or shorter time to achieve sustained SLE responder index-4 response (hazard ratio (HR): 2.52; 95% CI: 1.20-5.29; p = 0.015), independently of other factors. Decline of IL-6 levels through month 3 was greater in responders. In summary, belimumab treatment lowered IFN-α2, IL-6, and IL-10 levels, as well as levels of multiple autoantibodies, however after different time spans. Notably, anti-Sm positivity and early decline in IL-6 levels were associated with favorable treatment outcome.<br />Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
- Subjects :
- Adult
Antibodies, Antinuclear blood
Cytokines blood
Female
Humans
Interferon alpha-2 blood
Interleukin-10 blood
Interleukin-6 blood
Lupus Erythematosus, Systemic immunology
Lupus Erythematosus, Systemic pathology
Male
Middle Aged
Severity of Illness Index
Treatment Outcome
Antibodies, Monoclonal, Humanized administration & dosage
Autoantibodies blood
Lupus Erythematosus, Systemic blood
Lupus Erythematosus, Systemic drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1422-0067
- Volume :
- 21
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- International journal of molecular sciences
- Publication Type :
- Academic Journal
- Accession number :
- 32422945
- Full Text :
- https://doi.org/10.3390/ijms21103463